ClinicalTrials.gg
Active, not recruitingNCT05005949Updated Oct 23, 2026

STOP Persistent AF PAS

An observational study in Persistent Atrial Fibrillation, sponsored by Medtronic Cardiac Ablation Solutions. Active, not recruiting at 17 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Medtronic Cardiac Ablation Solutions (part of Medtronic) · Observational

Updated Oct 23, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
393
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 84 studies in Atrial Fibrillation by Medtronic — 8 open to participants now, 12 under way, none of them phase 3. Atrial Fibrillation · Medtronic.

Enrollment
13th of 18
393 · median 777
Started
2021
with 4 others
Observational
18 of 84
2 open now
Primary completion
2026-12
later than 2 of 11 live
Registered
70th of 84
by date

Among the 84 studies in Atrial Fibrillation by Medtronic, this one is the 13th largest by enrollment of the 18 observational ones that give a count, is one of 5 that started in 2021, is one of 18 observational ones, reaches primary completion later than 2 of the 11 other live ones, and was the 70th registered.

Atrial Fibrillation

4,016 studies on the registry are indexed under Atrial Fibrillation; 963 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

8 of the 84 studies in Atrial Fibrillation by Medtronic are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 609 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Atrial Fibrillation by Medtronic, or all of them as a file.
02

Study summary

The STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial.

Read the detailed description

The STOP Persistent AF Post Approval Study (PAS) is a sub-study to the Cryo Global Registry. The PAS is a prospective, global, multicenter, observational trial. The purpose of the PAS is to describe long-term clinical performance and safety data in the Persistent AF population treated with Arctic Front™ and Freezor™ MAX Families of Cardiac Cryoablation Catheters (hereafter referred to as Arctic Front™ Cardiac Cryoablation Catheter System). This PAS is a condition of the Pre-Market Approval order (P100010/S098) by the U.S. Food and Drug Administration. Up to 400 subjects will be enrolled to ensure 355 are treated. A minimum of 50% of patients will be enrolled and treated in the US. The follow-up duration for this post-approval study will be 36-months.

03

Conditions studied

  • Persistent Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects ≥ 18 years of age (or minimum age as required by local regulations) who have a recommendation for a pulmonary vein ablation with the Arctic Front™ Cardiac Cryoablation Catheter System may be approached regarding enrollment in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has been diagnosed with persistent AF.
  • Subject is ≥ 18 years of age or minimum age as required by local regulations.
  • Planned pulmonary vein isolation (PVI) procedure using commercially available Arctic Front™ Cardiac Cryoablation Catheter System.
  • Willing to comply with study requirements and give (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements.

Exclusion criteria

Exclusion Criteria:

  • Subject has had a prior atrial ablation (except for cavo-tricuspid isthmus (CTI) ablation for AFL).
  • Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager.
  • Subject with exclusion criteria required by local law.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
393 participants (actual)
Patient registry
No

Interventions

  • DeviceArctic Front™ Cardiac Cryoablation Catheter System

    Pulmonary vein isolation will be performed with the Arctic Front™ Cardiac Cryoablation Catheter System

06

What researchers measure

Primary outcomes

  1. Freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT)

    Estimate the 36-month freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT) recurrence using the Arctic Front™ Cardiac Cryoablation Catheter System.

    Time frame: 36 months

  2. Freedom from Primary Safety Events

    Estimate primary safety Adverse Event (AE) rates for cryoablation using the Arctic Front™ Cardiac Cryoablation Catheter System through 12-months.

    Time frame: 12 months

07

Study locations

17 sites
  • Hartford Hospital
    Hartford, Connecticut 06102, United States
  • Cardiology Associates of Fairfield County
    Stamford, Connecticut 06905-5522, United States
  • BayCare Medical Group Cardiology
    Clearwater, Florida 33756, United States
  • Heart Rhythms Solutions
    Davie, Florida 33328, United States
  • Carle Foundation Hospital
    Urbana, Illinois 61801-2500, United States
  • Henry Ford Heart & Vascular
    Detroit, Michigan 48202-2608, United States
  • Spectrum Health Hospitals
    Grand Rapids, Michigan 49525-6427, United States
  • The Lindner Research Center
    Cincinnati, Ohio 45219-2906, United States
  • Texas Cardiac Arrhythmia Research Foundation
    Austin, Texas 78705-1852, United States
  • Texas Health Research & Education Institute
    Dallas, Texas 75231, United States
  • Kepler Universitätsklinikum Med Campus III.
    Linz, 4020, Austria
  • St. Vinzenz-Hospital Köln
    Cologne, 50733, Germany
  • MVZ CCB Frankfurt und Main Taunus
    Frankfurt am Main, 60431, Germany
  • Städtische Kliniken München GmbH - Klinikum Bogenhausen
    München, 81925, Germany
  • Universitaria Pisana - Stabilimento di Cisanello
    Pisa, 56124, Italy
  • Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodz
    Lodz, 92-213, Poland
  • Liverpool Heart and Chest Hospital NHS Foundation Trust
    Liverpool, L14 3PE, United Kingdom
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Dec 2026, 64 months after the start.

Of 148 industry-sponsored observational studies under Atrial Fibrillation, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's planned 64 months is above that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Jul 2028 → Dec 2026 and completion Jul 2028 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2021
First posted
Aug 16, 2021
StartActual
Aug 19, 2021
Primary completionEst.
Dec 2026was Jul 2028
CompletionEst.
Dec 2026was Jul 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2028→Dec 2026
Oct 23, 2026
Study completion
Jul 2028→Dec 2026
Oct 23, 2026
Enrollment
400 (estimated)→393 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Primary completion Jul 2028→Dec 2026
    Study completion Jul 2028→Dec 2026
    Enrollment 400 (estimated)→393 (actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05005949
Responsible party
Sponsor
First posted
Aug 16, 2021
Start date
Aug 19, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 23, 2026

Study contacts

Khaldoun Tarakji, MD
study director · Medtronic CAS Chief Medical Officer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion